NRx Pharmaceuticals, Inc. announced that Ms. Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary, effective immediately. Ms. Daigneault's resignation is not the result of any disagreement with management or the Company's board of directors related to the Company's operations, policies, or practices. Ms. Daigneault is leaving the Company to pursue other personal and professional interests.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
3.51 USD | -1.40% | +21.50% | -22.61% |
May. 14 | Transcript : NRx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
May. 06 | NRx Pharmaceuticals Shares Rise 38% After Positive Drug Trial Data | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.61% | 36.68M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.39% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- BRPA Stock
- News NRx Pharmaceuticals, Inc.
- NRx Pharmaceuticals, Inc. Announces That Alessandra Daigneault Resigned as Chief Corporate Officer, General Counsel and Corporate Secretary